Myocardial ischemic injury

Cardiomyocyte ischemic injury refers to the pathological damage sustained by heart muscle cells when blood flow is insufficient to meet metabolic demands, typically due to coronary artery obstruction (StatPearls, 2023). This condition initiates a cascade of cellular events, including the depletion of adenosine triphosphate (ATP), failure of ion-exchange pumps, and subsequent intracellular calcium overload (Nature Reviews Cardiology, 2012). If the ischemia is prolonged, it leads to irreversible cell death through pathways such as necrosis, apoptosis, and mitophagy, ultimately resulting in myocardial infarction and potential heart failure (Circulation, 2017). While reperfusion is necessary to salvage tissue, it can paradoxically induce further damage known as ischemia-reperfusion injury (IRI) through the burst of reactive oxygen species and inflammatory cell infiltration (Journal of Clinical Investigation, 2013). Pharmacological management involves the use of antiplatelet agents, thrombolytics to restore flow, and beta-blockers or ACE inhibitors to reduce myocardial oxygen demand and prevent adverse ventricular remodeling (AHA/ACC Guidelines, 2021). Current research also explores cardioprotective agents that target specific mitochondrial and inflammatory pathways to minimize the extent of the injury during clinical interventions.

Other names

Cardiomyocyte ischemic injuryCardiac ischemiaMyocardial ischemia-reperfusion injuryHypoxic cardiomyocyte injuryHeart muscle ischemia

Pharmacological management focuses on restoring coronary blood flow, reducing myocardial oxygen demand, inhibiting platelet aggregation, and modulating the renin-angiotensin-aldosterone system to prevent adverse remodeling.